Osimertinib (AZD9291)
别名: Mereletinib
目录号:S7297 Purity: 99.99%
Osimertinib (AZD9291, Mereletinib)是口服不可逆的,突变选择性EGFR抑制剂,在 LoVo细胞中对Exon 19 缺失的 EGFR,L858R/T790M EGFR,和 WT EGFR的IC50分别为12.92,11.44 和 493.8 nM。Phase 3。
CAS: 1421373-65-0
客户使用Selleck的Osimertinib (AZD9291)发表文献399篇
- Signal Transduct Target Ther, 2024 9(1):216
- Signal Transduct Target Ther, 2024 9(1):65
- Nat Genet, 2024 10.1038/s41588-024-01948-8
- Nature, 2023 620(7973):393-401
- Mol Cancer, 2023 22(1):81
- Drug Resist Updat, 2023 71:100993
- J Thorac Oncol, 2023 10.1016/j.jtho.2023.10.017
- J Thorac Oncol, 2023 S1556-0864(23)00797-9
- Nature, 2022 603(7900):335-342
- Cancer Cell, 2022 40(7):754-767.e6
- Mol Cancer, 2022 21(1):43
- Cancer Discov, 2022 CD-22-1074
- Cancer Cell, 2021 S1535-6108(21)00383-4
- Cancer Cell, 2021 S1535-6108(21)00492-X
- Nat Nanotechnol, 2021 10.1038/s41565-021-00872-w
- Mol Cancer, 2021 20(1):17
- Cell, 2020 182(5):1232-1251.e22
- Cancer Cell, 2020 13;37(1):104-122e12
- Signal Transduct Target Ther, 2020 5(1):214
- J Hematol Oncol, 2020 13(1):169
- Cancer Discov, 2020 15 pii: CD-20-0116
- Sci Immunol, 2020 31;5(43) pii: eaav3937
- Nat Cancer, 2020 1(3):359-369
- J Thorac Oncol, 2020 15(5):752-765
- Nat Med, 2019 25(1):111-118
- Cancer Cell, 2019 10.1016/j.ccell.2019.09.001
- Signal Transduct Target Ther, 2019
- J Thorac Oncol, 2019 14(9):1556-1566
- J Thorac Oncol, 2019 14(4):656-671
- Nat Med, 2018 24(5):638-646
- J Hematol Oncol, 2018 11(1):109
- Nat Biomed Eng, 2018 2(4):239-253
- J Thorac Oncol, 2018 13(7):915-925
- J Thorac Oncol, 2017 12(5):884-889
- Cancer Discov, 2015 5(11):1155-63
- Cancer Discov, 2015 5(7):713-22
- Cytokine, 2025 185:156802
- Nat Commun, 2024 15(1):2742
- Nat Commun, 2024 15(1):3741
- J Extracell Vesicles, 2024 13(7):e12494
- Adv Sci (Weinh), 2024 11(38):e2400370
- Cell Rep Med, 2024 5(3):101471
- J Exp Clin Cancer Res, 2024 43(1):302
- Cell Death Dis, 2024 15(9):644
- Oncogene, 2024 10.1038/s41388-024-03105-1
- NPJ Precis Oncol, 2024 8(1):60
- NPJ Precis Oncol, 2024 8(1):3
- Cancer Metab, 2024 12(1):37
- iScience, 2024 27(8):110499
- iScience, 2024 27(2):108839
- Int J Mol Sci, 2024 25(7)3992
- Am J Cancer Res, 2024 14(1):33-51
- Lung Cancer, 2024 15:55-67
- Cancers (Basel), 2024 16(13)2490
- Cancers (Basel), 2024 16(23)3941
- Cancers (Basel), 2024 16(6)1170
- Transl Oncol, 2024 43:101895
- Transl Oncol, 2024 39:101834
- Transl Oncol, 2024 49:102108
- Biomedicines, 2024 12(7)1412
- Sci Rep, 2024 14(1):24429
- Microbiol Spectr, 2024 e0158324.
- Oncol Res, 2024 32(6):1119-1128
- Biochim Biophys Acta Gen Subj, 2024 1868(10):130675
- J Biomed Res, 2024 1-15.
- Discov Oncol, 2024 15(1):678
- JTO Clin Res Rep, 2024 5(4):100668
- STAR Protoc, 2024 5(2):102987
- bioRxiv, 2024 2024.09.26.615226
- Bioact Mater, 2023 27:337-347
- Nat Commun, 2023 14(1):3183
- Nat Commun, 2023 14(1):3468
- Acta Pharm Sin B, 2023 13(6):2613-2627
- J Exp Clin Cancer Res, 2023 10.1186/s13046-023-02866-z
- Proc Natl Acad Sci U S A, 2023 120(4):e2218118120
- Cell Death Dis, 2023 14(10):657
- Br J Cancer, 2023 10.1038/s41416-023-02196-z
- Br J Cancer, 2023 128(12):2186-2196
- Cell Chem Biol, 2023 30(10):1211-1222.e5
- Talanta, 2023 259:124553
- iScience, 2023 26(7):107105
- iScience, 2023 26(3):106082
- Clin Epigenetics, 2023 15(1):36
- Int J Mol Sci, 2023 24(2)997
- Front Pharmacol, 2023 14:1177003
- Front Pharmacol, 2023 14:1189245
- Front Pharmacol, 2023 14:1093017
- Cancers (Basel), 2023 15(4)1092
- Cancers (Basel), 2023 15(9)2589
- Transl Lung Cancer Res, 2023 12(10):2098-2112
- Cancer Med, 2023 10.1002/cam4.6232
- J Cancer, 2023 14(1):152-162
- Exp Cell Res, 2023 424(1):113503
- Exp Cell Res, 2023 430(1):113722
- Biochem Biophys Res Commun, 2023 645:24-29
- Thorac Cancer, 2023 14(19):1843-1856
- bioRxiv, 2023 2023.03.03.531059
- JTO Clin Res Rep, 2023 4(6):100525
- JTO Clin Res Rep, 2023 4(9):100554
- Research Square, 2023 10.21203/rs.3.rs-3646385/v1
- bioRxiv, 2023 2023.11.30.569313
- bioRxiv, 2023 2023.07.02.547443
- Sci Transl Med, 2022 14(638):eabc7480
- Nat Commun, 2022 13(1):6791
- Mol Cell, 2022 S1097-2765(22)00434-8
- J Clin Invest, 2022 132(13)e145099
- Cell Rep Med, 2022 3(1):100492
- Clin Cancer Res, 2022 CCR-22-2180
- Cancer Res, 2022 CAN-22-0770
- Cancer Res, 2022 82(8):1534-1547
- Cancer Res, 2022 canres.0394.2022-2-3 21:03:12.200
- Genomics Proteomics Bioinformatics, 2022 S1672-0229(22)00142-5
- Pharmacol Res, 2022 179:106209
- Cell Death Dis, 2022 13(1):41
- Cell Death Dis, 2022 13(7):611
- Cell Rep, 2022 41(11):111827
- Eur J Cancer, 2022 170:91-102
- Acta Pharmacol Sin, 2022 10.1038/s41401-022-00905-7
- Cell Mol Life Sci, 2022 80(1):6
- Transl Res, 2022 S1931-5244(22)00244-4
- Cell Oncol (Dordr), 2022 10.1007/s13402-022-00750-0
- Mol Oncol, 2022 16(16):3017-3033
- Cancer Gene Ther, 2022 29(12):1878-1894
- Commun Biol, 2022 5(1):1052
- ACS Biomater Sci Eng, 2022 8-10:4535-4546
- Cancer Cell Int, 2022 22(1):358
- Cancer Sci, 2022 10.1111/cas.15617
- Front Pharmacol, 2022 13:1019451
- Front Pharmacol, 2022 13:1032975
- Front Pharmacol, 2022 13:895744
- Front Chem, 2022 10:837987
- Cancers (Basel), 2022 14(14)3430
- Cancers (Basel), 2022 15(1)124
- Cancers (Basel), 2022 14(6)1512
- Transl Oncol, 2022 22:101461
- J Pers Med, 2022 12(2)258
- FASEB J, 2022 36(5):e22270
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Cancer Med, 2022 10.1002/cam4.4504
- Transl Lung Cancer Res, 2022 11(5):722-734
- J Cancer, 2022 13(15):3660-3673
- J Cancer, 2022 13(9):2798-2809
- BMC Cancer, 2022 22(1):752
- Mol Immunol, 2022 153:135-145
- Clin Transl Oncol, 2022 10.1007/s12094-022-02854-3
- Invest New Drugs, 2022 40(2):265-273
- BMC Pulm Med, 2022 22(1):36
- Anticancer Res, 2022 42(2):709-722
- Sci Adv, 2022 8(4):eabi7711
- Nat Commun, 2021 12(1):4789
- Nat Commun, 2021 12(1):2346
- Nat Commun, 2021 12(1):5919
- Nat Chem Biol, 2021 10.1038/s41589-021-00947-8
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-21-3359
- J Exp Clin Cancer Res, 2021 40(1):371
- Cancer Res, 2021 canres.1153.2021
- Cancer Res, 2021 canres.CAN-21-2426-E.2021
- EBioMedicine, 2021 64:103220
- Pharmacol Res, 2021 170:105701
- Cell Rep, 2021 37(1):109788
- Mol Ther Nucleic Acids, 2021 26:798-812
- Cell Rep, 2021 35(8):109181
- Mol Ther Nucleic Acids, 2021 26:613-624
- Cell Rep, 2021 34(3):108647
- Acta Pharmacol Sin, 2021 10.1038/s41401-020-00577-1
- Acta Pharmacol Sin, 2021 10.1038/s41401-021-00691-8
- NPJ Precis Oncol, 2021 5(1):65
- NPJ Precis Oncol, 2021 5(1):32
- NPJ Precis Oncol, 2021 5(1):91
- J Med Chem, 2021 10.1021/acs.jmedchem.1c00848
- J Med Chem, 2021 10.1021/acs.jmedchem.1c00932
- mBio, 2021 12(6):e0322821
- Oncogenesis, 2021 10(3):29
- Oncogenesis, 2021 10(7):56
- Arch Toxicol, 2021 10.1007/s00204-021-03147-4
- Biochem Pharmacol, 2021 190:114642
- Cancer Sci, 2021 112(5):1963-1974
- Mol Cancer Ther, 2021 molcanther.0371.2021
- Cancer Sci, 2021 112(9):3810-3821
- Cancer Sci, 2021 112(9):3784-3795
- Cancer Sci, 2021 112(5):1853-1864
- Mol Cancer Ther, 2021 20(9):1653-1662
- Int J Mol Sci, 2021 22(8)4005
- Lung Cancer, 2021 162:79-85
- Lung Cancer, 2021 154:84-91
- Lung Cancer, 2021 158:137-145
- Cancers (Basel), 2021 13(12)2987
- Cancers (Basel), 2021 13(18)4651
- Cancers (Basel), 2021 13(15)3906
- Aging (Albany NY), 2021 13(5):6890-6903
- Cancers (Basel), 2021 13(23)6005
- Biochim Biophys Acta Mol Cell Res, 2021 1868(6):119016
- Biochim Biophys Acta Mol Cell Res, 2021 1869(1):119144
- Front Oncol, 2021 11:665045
- Front Oncol, 2021 11:711043
- Ann Transl Med, 2021 9(14):1150
- Cancer Res Treat, 2021 10.4143/crt.2021.385
- Sci Rep, 2021 11(1):19667
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Transl Lung Cancer Res, 2021 10(1):128-142
- Transl Lung Cancer Res, 2021 10(8):3659-3670
- Transl Lung Cancer Res, 2021 10(3):1277-1291
- Toxicol Appl Pharmacol, 2021 419:115518
- Exp Cell Res, 2021 409(2):112940
- Toxicol Lett, 2021 348:10-17
- BMC Pulm Med, 2021 21(1):163
- Biochem Biophys Res Commun, 2021 571:38-45
- Thorac Cancer, 2021 12(11):1690-1698
- Oncol Lett, 2021 22(3):639
- Thorac Cancer, 2021 10.1111/1759-7714.13931
- Oncol Lett, 2021 21(5):418
- Exp Ther Med, 2021 21(6):654
- Jpn J Clin Oncol, 2021 hyab048
- J Vis Exp, 2021 -177
- CU Digital Repository, 2021 N/A
- Nat Commun, 2020 11(1):4607
- Acta Neuropathol, 2020 139(6):1071-1088
- Theranostics, 2020 15;10(14):6122-6135
- Clin Cancer Res, 2020 20 pii: clincanres
- Clin Cancer Res, 2020 10.1158/1078-0432.CCR-19-2321
- Clin Cancer Res, 2020 10.1158/1078-0432
- Cancer Res, 2020 80(21):4655-4667
- EMBO Mol Med, 2020 e11099
- Cancer Lett, 2020 28;483:46-58
- Cell Death Dis, 2020 14;11(4):230
- Br J Cancer, 2020 22
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-0443-1
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-0457-8
- Oncogene, 2020 10.1038/s41388-020-01497-4
- Food Funct, 2020 11(3):2714-2724
- Cells, 2020 9(12)E2596
- Cancer Sci, 2020 111(7):2374-2384
- Cancer Sci, 2020 111(10):3813-3823
- Front Cell Dev Biol, 2020 8:652
- Pharmaceutics, 2020 12(10)E939
- Lung Cancer, 2020 5;145:48-57
- J Cell Mol Med, 2020 10.1111/jcmm.16135
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-20-0664
- Cancers (Basel), 2020 13(1)111
- Mol Cancer Res, 2020 18(4):549-559
- Cancers (Basel), 2020 12(3)
- Front Oncol, 2020 9:1503
- Viruses, 2020 12(11)E1294
- Ann Transl Med, 2020 8(6):366
- Sci Rep, 2020 17;10(1):2735
- Sci Rep, 2020 10(1):11236
- Environ Toxicol, 2020 10.1002/tox.22899
- J Oncol, 2020 17;2020:6249829
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Mol Genet, 2020 ddaa268
- Biochem Biophys Res Commun, 2020 534:1-7
- Physiol Rep, 2020 8(13):e14490
- Rapid Commun Mass Spectrom, 2020 10.1002/rcm.8955
- J Med Invest, 2020 67(3.4):343-350
- Nat Commun, 2019 10(1):2701
- Neuro Oncol, 2019 10.1093/neuonc/noz206
- Acta Pharm Sin B, 2019 9(6):1193-1203
- Biomaterials, 2019 219:119400
- Clin Cancer Res, 2019 25(11):3329-3340
- J Exp Clin Cancer Res, 2019 38(1):481
- Cancer Res, 2019 10.1158/0008-5472.CAN-18-2808
- Cell Syst, 2019 8(2):97-108
- Cell Syst, 2019 10.1016/j.cels.2019.10.002
- Int J Biol Sci, 2019 15(12):2607-2614
- Oncogene, 2019 38(5):656-670
- Oncogene, 2019 38(37):6399-6413
- JCI Insight, 2019 4(21)
- Cell Biosci, 2019 9:60
- Cell Mol Gastroenterol Hepatol, 2019 7(1):161-184
- Int J Cancer, 2019 145(5):1432-1444
- Mol Cancer Ther, 2019 18(1):112-126
- Mol Cancer Ther, 2019 18(9):1593-1601
- Cancer Sci, 2019 110(11):3584-3594
- Respir Res, 2019 20(1-:270
- Oncotarget, 2019 10(26):2546-2560
- Lung Cancer, 2019 137:85-93
- J Cell Mol Med, 2019 23(11):7427-7437
- Lung Cancer, 2019 127:146-152
- Am J Cancer Res, 2019 9(8):1708-1721
- Cancers, 2019 11(3)
- Ann Transl Med, 2019 7(22):651
- Sci Rep, 2019
- Sci Rep, 2019 9(1):5692
- Oncol Rep, 2019 41(2):1059-1066
- J Cell Biochem, 2019 120(1):756-767
- Transl Lung Cancer Res, 2019 8(4):340-351
- Toxicol Appl Pharmacol, 2019 379:114662
- Biomed Res Int, 2019 2019:3129748
- Clin Lung Cancer, 2019 20(3):167-177
- Cancer Manag Res, 2019 11:3419-3432
- Thorac Cancer, 2019 10(10):1868-1878
- Oncol Lett, 2019 18(1):955-961
- FEBS Open Bio, 2019 9(10):1689-1704
- Breast Cancer (Dove Med Press), 2019 11:231-241
- Transl Cancer Res, 2019 8(5):2151-2163
- Zhongguo Fei Ai Za Zhi, 2019 22(5):264-270
- Nat Commun, 2018 9(1):4655
- Cancer Commun (Lond), 2018 38(1):19
- Clin Cancer Res, 2018 24(13):3097-3107
- Clin Cancer Res, 2018 24(22):5610-5621
- Cancer Res, 2018 10.1158/0008-5472.CAN-18-0505
- EBioMedicine, 2018 29:112-127
- Proc Natl Acad Sci U S A, 2018 115(26):E6030-E6038
- JCI Insight, 2018 3(11)
- JCI Insight, 2018 3(24)
- Sci Signal, 2018 11(549)
- Mol Cancer Ther, 2018 17(4):740-750
- Mol Cancer Ther, 2018 17(10):2257-2265
- Nanomedicine (Lond), 2018 13(10):1107-1120
- Oncotarget, 2018 9(76):34240-34258
- Oncotarget, 2018 9(51):29680-29697
- Oncotarget, 2018 9(101):37520-37533
- Front Cell Neurosci, 2018 12:21
- Lung Cancer, 2018 126:72-79
- Neoplasia, 2018 20(8):826-837
- FASEB J, 2018 10.1096/fj.201800011R
- Sci Rep, 2018 8(1):14896
- Sci Rep, 2018 8(1):18043
- Environ Toxicol, 2018 33(11):1153-1159
- Oncol Rep, 2018 40(2):1046-1054
- Cancer Med, 2018 7(1):208-218
- Endocr Relat Cancer, 2018 25(1):99-109
- Cancer Biol Ther, 2018 19(3):239-247
- J Cancer Res Clin Oncol, 2018 10.1007/s00432-018-2668-7
- Invest New Drugs, 2018 36(6):999-1005
- Radiat Res, 2018 189(3):283-291
- Pharmazie, 2018 73(11):630-634
- Sci Transl Med, 2017 9(415)
- Nat Commun, 2017 8:13897
- Nat Commun, 2017 8(1):410
- Neuro Oncol, 2017 19(12):1628-1639
- Clin Cancer Res, 2017 23(12):3139-3149
- Cancer Res, 2017 77(13):3527-3539
- Cancer Res, 2017 10.1158/0008-5472
- Cancer Res, 2017 77(5):1200-1211
- Cancer Res, 2017 77(11):2990-3000
- Genes Dev, 2017 31(2):184-196
- J Natl Cancer Inst, 2017 1;109(9):djx014
- Cell Rep, 2017 21(11):3298-3309
- Elife, 2017 6
- J Med Chem, 2017 60(17):7447-7458
- Genome Res, 2017 27(4):613-625
- Eur J Med Chem, 2017 140:510-527
- Mol Oncol, 2017 11(6):670-681
- Arch Toxicol, 2017 91(8):2921-2938
- Mol Cancer Ther, 2017 16(11):2572-2585
- Mol Cancer Ther, 2017 16(11):2563-2571
- Mol Cancer Ther, 2017 16(3):506-515
- Mol Cancer Ther, 2017
- Mol Cancer Ther, 2017 16(10-:2130-2143
- J Mol Biol, 2017 429(14):2211-2230
- Oncotarget, 2017 8(62):105479-105491
- Oncotarget, 2017 8(29):47305-47316
- Oncotarget, 2017 8(55):93825-93838
- Oncotarget, 2017 8(65):109319-109331
- Oncotarget, 2017 8(62):104894-104912
- Oncotarget, 2017
- Oncotarget, 2017 8(22):36331-36338
- Oncotarget, 2017 9(2):1641-1655
- Lung Cancer, 2017 108:96-102
- Lung Cancer, 2017 109:1-8
- Mol Cancer Res, 2017 15(11):1542-1550
- Mol Cancer Res, 2017 15(7):852-861
- Mol Cancer Res, 2017
- Mol Pharm, 2017 14(7):2368-2377
- Sci Rep, 2017 7(1):15441
- Sci Rep, 2017 7:44206
- Sci Rep, 2017 7:44089
- Onco Targets Ther, 2017 10:5281-5288
- Transl Lung Cancer Res, 2017 6(5):600-610
- Toxicol Appl Pharmacol, 2017 321:18-26
- Toxicol Sci, 2017 162(1):146-166
- Clin Lung Cancer, 2017 18(3):281-285
- Oncol Lett, 2017 14(4):4349-4354
- J Vis Exp, 2017 (126)
- Nat Commun, 2016 7:11815
- Mol Cell, 2016 63(3):526-38
- Cancer Immunol Res, 2016 4(11):936-947
- Oncogene, 2016 10.1038/onc.2016.216
- J Med Chem, 2016 59(13):6187-200
- Mol Cancer Ther, 2016 15(12):3040-3054
- Cancer Sci, 2016 107(8):1134-40
- Oncotarget, 2016 7(51):84951-84964
- Oncotarget, 2016 7(30):47998-48010
- Oncotarget, 2016 7(17):23608-32
- Oncotarget, 2016 7(4):3847-56
- Mol Pharm, 2016 13(6):2117-25
- Sci Rep, 2016 6:37997
- Clin Cancer Res, 2015 21(23):5305-13
- Clin Cancer Res, 2015 10.1158/1078-0432.CCR-15-0560
- Sci Signal, 2015
- J Med Chem, 2015 58(16):6589-606
- J Biol Chem, 2015 290(28):17495-504
- PLoS One, 2015 10(11):e0143333
- J Natl Compr Canc Netw, 2013 11(10):1249-61
- Methods Mol Biol, 2011 685:91-109
- Expert Opin Pharmacother, 2010 11(8):1263-76
化学信息&溶解度
分子量 | 499.61 |
分子式 | C28 H33 N7 O2 |
CAS号 | 1421373-65-0 |
Smiles | CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 99 mg/mL ( 198.15 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 99 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 200.15 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 33 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 200.15 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 200.15 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 25 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5% DMSO
95% Corn oil
浓度:0.8mg/ml
(1.60mM)
操作示例:以1 mL工作液为例,取50μL 16mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:7.5mg/ml
(15.01mM)
操作示例:以 1 mL 工作液为例,取50μL150mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5%DMSO
Corn oil
浓度:5mg/ml
(10.01mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。